← Back to patent-cliff list
Brenipatide
Tier C — Watch / tradeBrenipatide
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GIPR
Indications (approved)：Depressive disorder, Alcohol abuse, Major depressive disorder, Chronic obstructive pulmonary disease, Irritable bowel syndrome, Diarrhoea, Constipation, Asthma
Regional status
US
Phase III
2025-10-15
EU
Phase III
2025-10-15
China
Phase III
2025-10-15
Japan
Phase III
2025-10-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Brenipatide?
Approved indications include: Depressive disorder, Alcohol abuse, Major depressive disorder, Chronic obstructive pulmonary disease, Irritable bowel syndrome, Diarrhoea, Constipation, Asthma.
When does the Brenipatide patent expire?
No public expiry year is available for Brenipatide yet; this page updates once verified.
How do I get a quote for Brenipatide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22